TechNavio recognizes the following companies as the key players in the Global Nanomedicine market: Abbott Laboratories, AstraZeneca plc, Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, and Pfizer Inc.
Commenting on the report, an analyst from TechNavio’s team said: “One of the main trends witnessed in the Global Nanomedicine market is the emergence of emergence of personalized medicines. Over the years, research activities in the Healthcare industry have changed significantly. There has been a paradigm shift from blockbuster drugs to a more personalized medicine approach. More emphasis is being laid on formulating drugs on the basis of an individual’s unique genome and immune response. The Global Nanomedicine market is witnessing a significant demand for personalized medicines because of their ability to provide customized treatments to patients. These customized treatments are based on the medical conditions and genetics of the patients.”
According to the report, one of the main factors driving the market is the emergence of nanorobotics. Although the Global Nanorobotics market is still in its initial stage, there is great potential for these devices to be used in the field of nanomedicine. For instance, researchers are planning to build nanorobots using DNA Origami, a method in which the arrangement of DNA’s corresponding chemical base pairs is taken to create different nano-structures.
Further, the report states that one of the main challenges is long approval process and stringent regulations. The long approval procedures of FDA and other regulatory organizations differentiate nanomedicine products from the nanotechnology products used in other industries. Hence, the expenditure to establish any nanomedicine product in the consumer market is enormous.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Ablynx NV, Acusphere Inc., Aphios Corp., Arrowhead Research Corp., BioForce, Nanosciences Holdings Inc., Bio-Gate AG, Biophan Technologies Inc., BioSante Pharmaceuticals Inc., CombiMatrix Corp., Enzon Pharmaceuticals Inc., GE Healthcare Ltd., Gilead Sciences Inc., IDEX Corp., IGI Laboratories Inc., Kereos Inc., Kimberly-Clark Corp., MIV Therapeutics Inc., Nanobiotix S.A., NanoCarrier Co. Ltd., Nanogen Inc., NanoLogix Inc., NanoMed Pharmaceuticals Inc., Nanotherapeutics Inc., NanoViricides Inc., Paladin Labs Inc., pSivida Corp., Qiagen N.V., Roche Holding AG, Skyepharma PLC, Smith & Nephew plc, Starpharma Holdings Ltd., Stryker Corp., and Tecan Group Ltd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/report/global-nanomedicine-market-2012-2016
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our market research, please visit https://www.technavio.com/healthcare-chemicals-food-retail
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report -Global Nanomedicine Market 2012-2016
